You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,519,131


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,519,131
Title:Benzazepine compounds, conjugates, and uses thereof
Abstract: Benzazepine compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed benzazepine compounds are useful, among other things, in the treating of cancer and modulating TLR8. Additionally, benzazepine compounds incorporated into a conjugate with an antibody construct are described herein.
Inventor(s): Coburn; Craig Alan (Seattle, WA), Baum; Peter Robert (Seattle, WA), Smith; Sean Wesley (Seattle, WA)
Assignee: SILVERBACK THERAPEUTICS, INC. (Seattle, WA)
Application Number:15/973,506
Patent Claims:1. A method of treating breast cancer, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a conjugate having the following formula: ##STR00339## wherein Antibody is an antibody construct, L.sup.3 is a linker, and D is a compound represented by the structure of Formula (IIIA): ##STR00340## or a pharmaceutically acceptable salt thereof, wherein: represents an optional double bond; L.sup.11 is selected from --C(O)-- and --C(O)N(R.sup.10)--*, wherein * represents where L.sup.11 is bound to R.sup.6; L.sup.2 is selected from a bond and --C(O)--; R.sup.1 and R.sup.2 are independently selected from hydrogen, C.sub.1-10 alkyl, C.sub.2-10 alkenyl and C.sub.1-10 alkynyl; R.sup.4 is selected from: --OR.sup.10, --N(R.sup.10).sub.2, --C(O)N(R.sup.10).sub.2, --C(O)R.sup.10, --C(O)OR.sup.10, --S(O)R.sup.10, --S(O).sub.2R.sup.10, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, and C.sub.2-10 alkynyl; R.sup.6 is selected from phenyl and 5- or 6-membered heteroaryl, any one of which is substituted with one or more substituents selected from R.sup.7 and R.sup.6 is further optionally substituted by one or more additional substituents independently selected from R.sup.12; R.sup.7 is selected from --C(O)NHNH.sub.2, --C(O)NH--C.sub.1-3alkylene-NH(R.sup.10), --C(O)CH.sub.3, --C.sub.1-3alkylene-NHC(O)OR.sup.11, --C.sub.1-3alkylene-NHC(O)R.sup.10, --C.sub.1-3alkylene-NHC(O)NHR.sup.10, --C.sub.1-3alkylene-NHC(O)--C.sub.1-3alkylene-R.sup.10, and a 3- to 12-membered heterocycle optionally substituted with one or more substituents independently selected from R.sup.12; R.sup.10 is independently selected at each occurrence from hydrogen, --NH.sub.2, and --C(O)OCH.sub.2C.sub.6H.sub.5; and C.sub.1-10alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-12 carbocycle, and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, --OH, --CN, --NO.sub.2, --NH.sub.2, .dbd.O, .dbd.S, --C(O)OCH.sub.2C.sub.6H.sub.5, --NHC(O)OCH.sub.2C.sub.6H.sub.5, --C.sub.1-10 alkyl, --C.sub.1-10 haloalkyl, --O--C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, C.sub.3-12 carbocycle, and 3- to 12-membered heterocycle; R.sup.11 is selected from C.sub.3-12 carbocycle and 3- to 12-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from R.sup.12; and R.sup.12 is independently selected at each occurrence from halogen, --OR.sup.10, --SR.sup.10, --N(R.sup.10).sub.2, --C(O)R.sup.10, --C(O)N(R.sup.10).sub.2, --N(R.sup.10)C(O)R.sup.10, --C(O)OR.sup.10, --OC(O)R.sup.10, --S(O)R.sup.10, --S(O).sub.2R.sup.10, --P(O)(OR.sup.10).sub.2, --OP(O)(OR.sup.10).sub.2, --NO.sub.2, .dbd.O, .dbd.S, .dbd.N(R.sup.10), and --CN; C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, each of which is optionally substituted with one or more substituents independently selected from halogen, --OR.sup.10, --SR.sup.10, --N(R.sup.10).sub.2, --C(O)R.sup.10, --C(O)N(R.sup.10).sub.2, --N(R.sup.10)C(O)R.sup.10, --C(O)OR.sup.10, --OC(O)R.sup.10, --S(O)R.sup.10, --S(O).sub.2R.sup.10, --P(O)(OR.sup.10).sub.2, --OP(O)(OR.sup.10).sub.2, --NO.sub.2, .dbd.O, .dbd.S, .dbd.N(R.sup.10), --CN, C.sub.3-10 carbocycle and 3- to 10-membered heterocycle; and C.sub.3-10 carbocycle and 3- to 10-membered heterocycle optionally substituted with one or more substituents independently selected from halogen, --OR.sup.10, --SR.sup.10, --N(R.sup.10).sub.2, --C(O)R.sup.10, --C(O)N(R.sup.10).sub.2, --N(R.sup.10)C(O)R.sup.10, --C(O)OR.sup.10, --OC(O)R.sup.10, --S(O)R.sup.10, --S(O).sub.2R.sup.10, --P(O)(OR.sup.10).sub.2, --OP(O)(OR.sup.10).sub.2, --NO.sub.2, .dbd.O, .dbd.S, .dbd.N(R.sup.10), --CN, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, and C.sub.2-6 alkynyl, and wherein the antibody construct specifically binds to human HER2, TROP2 or Liv-1, and wherein L.sup.3 is bound to a substitutable nitrogen or oxygen of the compound or salt of Formula (IIIA).

2. The method of claim 1, wherein the antibody construct comprises pertuzumab, trastuzumab, sacituzumab, ladiratuzumab or an antigen binding fragment thereof.

3. The method of claim 2, wherein the average drug-antibody ratio of the composition is from about 2 to about 8.

4. The method of claim 1, wherein the compound or salt of Formula (IIIA) is selected from: ##STR00341## ##STR00342## ##STR00343## ##STR00344## ##STR00345## ##STR00346## ##STR00347## and a salt of any one thereof.

5. The method of claim 1, wherein L.sup.3 is covalently bound to a substitutable nitrogen of the compound or salt or Formula (IIIA).

6. The method of claim 1, wherein each L.sup.3 is attached to the antibody construct at a lysine or cysteine residue.

7. The method of claim 1, wherein L.sup.3 is a noncleavable linker.

8. The method of claim 7, wherein L.sup.3 is represented as follows: ##STR00348## wherein RX* comprises a bond, a succinimide moiety, or a hydrolyzed succinimide moiety bound to a residue of the antibody construct, wherein ##STR00349## on RX* represents the point of attachment to the residue of the antibody construct, and n=0-9.

9. The method of claim 1, wherein L.sup.3 is a cleavable linker.

10. The method of claim 9, wherein L.sup.3 is cleavable by a lysosomal enzyme.

11. The method of claim 9, wherein L.sup.3 is represented by the formula: ##STR00350## wherein L.sup.4 represents the C-terminal of the peptide and L.sup.5 is selected from a bond, alkylene and heteroalkylene, wherein L.sup.5 is optionally substituted with one or more groups independently selected from R.sup.32; RX* comprises a bond, a succinimide moiety, or a hydrolyzed succinimide moiety bound to a residue of an antibody construct, wherein ##STR00351## on RX* represents the point of attachment to the residue of the antibody construct; and, R.sup.32 is independently selected at each occurrence from halogen, --OH, --CN, --O-alkyl, --SH, .dbd.O, .dbd.S, --NH.sub.2, --NO.sub.2; and C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, each of which is optionally substituted with one or more substituents independently selected from halogen, --OH, --CN, --O-- alkyl, --SH, .dbd.O, .dbd.S, --NH.sub.2, --NO.sub.2.

12. The method of claim 11, wherein the peptide of L.sup.3 comprises Val-Cit or Val-Ala.

13. The method of claim 1, wherein the pharmaceutical composition comprises at least one pharmaceutically acceptable excipient.

Details for Patent 10,519,131

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2037-03-15
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2037-03-15
Genentech, Inc. PERJETA pertuzumab Injection 125409 06/08/2012 ⤷  Try a Trial 2037-03-15
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2037-03-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.